More Money! Why Tekmira is Worth Revisiting
Research - -TKMR remains an interest at PropThink despite rising 260% since coverage in January. Stock is undervalued relative to peers, has an expanding pipeline, and is … Continue Reading
Read nowSearch Results for endo health
Alexion’s Beat, Raise, and Improved Tax Status Has Broader Implications
Insights - With the release of its full-year ’13 and Q4 financials on Thursday, Alexion Pharmaceuticals (ALXN) beat on both earnings and revenue, now guiding for 2014 … Continue Reading
Read now
Three Updates on Three Names PropThink Suggested for the First Half of This Year
Research - With the JP Morgan Healthcare conference in the rearview, here are updates on a few names that PropThink suggested already this year, all of which … Continue Reading
Premium
Completed Enrollment Sets Up Catalyst for Threshold Pharmaceuticals
Insights - Threshold Pharmaceuticals (THLD) announced that the target enrollment of 620 patients with advanced soft tissue sarcoma has been achieved in the company’s pivotal phase 3 … Continue Reading
Read nowHappy Holidays! PropThink’s Weekly Recap
Recap - Happy holidays from the PropThink editorial team! We hope you’re enjoying time with friends and family as we wrap up another busy holiday season and … Continue Reading
Read now
The Turnaround Begins: Icahn Backs Hologic Board & Management
Insights - In two press releases on Monday morning, Hologic (HOLX) announced the hiring of a new CEO and the addition of two new independent members to … Continue Reading
Premium
BioDelivery Sciences: Delivering Profits in 2014
Research - In the biotechnology sector, innovation can come in one of a few forms, including novel drugs or novel ways to deliver existing drugs. BioDelivery Sciences … Continue Reading
Premium